CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: Population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe

BMC Pharmacology and Toxicology

Volumn 16, Issue 1, 2015, Pages

  Dhoro, Milcah ^a,b   Zvada, Simbarashe ^c   Ngara, Bernard ^a   Nhachi, Charles ^b   Kadzirange, Gerald ^b   Chonzi, Prosper ^d   Masimirembwa, Collen ^a  

^a African Institute of Biomedical Science and Technology   (Zimbabwe)

^b UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

^d University of Zimbabwe Department of Medicine College of Health Sciences ^*  (Zimbabwe)

Author keywords

Central nervous system adverse effects; CYP2B6; Efavirenz; HIV; Tuberculosis; Zimbabwe

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; EFAVIRENZ; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1; RIFAMPICIN; ABCB1 PROTEIN, HUMAN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYP2A6 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN;

ABCB1 GENE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALLELE; ARTICLE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; CYP2A6 GENE; CYP2B6 GENE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG SAFETY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HALLUCINATION; HEADACHE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NONLINEAR SYSTEM; OPTIMAL DRUG DOSE; PHARMACOGENETICS; SEX DIFFERENCE; TUBERCULOSIS; ZIMBABWE; ACQUIRED IMMUNODEFICIENCY SYNDROME; BIOLOGICAL MODEL; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED; COMPLICATION; DRUG INTERACTION; GENETICS; METABOLISM; SEXUAL DEVELOPMENT; SLEEP DISORDER;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ALLELES; ANTI-HIV AGENTS; BENZOXAZINES; BODY WEIGHT; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2A6; CYTOCHROME P-450 CYP2B6; DRUG INTERACTIONS; FEMALE; HALLUCINATIONS; HEADACHE; HUMANS; MALE; MODELS, BIOLOGICAL; P-GLYCOPROTEINS; RIFAMPIN; SEX CHARACTERISTICS; SLEEP WAKE DISORDERS; TUBERCULOSIS; ZIMBABWE;

EID: 84938885862     PISSN: 20506511     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/s40360-015-0004-2     Document Type: Article

References (52)

1. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-5.
2. Scourfield A, Zheng J, Chinthapalli S. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS. 2012;26:1399-401.
3. Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS. 2006;20:542-8.
4. Guidelines for Antiretroviral Therapy in Zimbabwe. The National Drug and Therapeutics Policy Advisory Committee (NDTPAC) and The AIDS and TB Unit, Ministry of Health and Child Welfare (MOHCW), Harare, Republic of Zimbabwe. 2010
5. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 2007;45:1230-7.
6. Van Luin M, Gras L, Richter C. Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. J Acquir Immune Defic Syndr. 2009;52:240-5.
7. Figueroa S, Iglesias Gomez A, Sanchez Martin A. Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV. Clin Drug Investig. 2010;30:405-11.
8. Puls R. Encore1 Study Group. A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo controlled, non-inferiority trial. In 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3; Kuala Lumpur. 2013; Abstract WELBB01
9. World Health Organization. WHO Report. Global Tuberculosis Control: Country Profile: South Africa. [apps.who.int/iris/bitstream/10665/44728/1/9789241564380_eng.pdf]
10. Ministry of Health and Child Welfare Zimbabwe National HIV Estimates. 2010.
11. Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther. 2009;85:485-94.
12. Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2010;202:717-22.
13. Mukonzo JK, Roshammar D, Waako P. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol. 2009;68:690-9.
14. Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics. 2010;11:1223-34.
15. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306:287-300.
16. Di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics. 2009;19:300-9.
17. Winzer RLP, Zilly M, Tollmann F, Schubert J, Klinker HWB. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res. 2003;8:531-4.
18. Dirson G, Fernandez C, Hindlet P, Roux F, German-Fattal M, Gimenez F. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. Pharm Res. 2006;23:1525-32.
19. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007;8:743-59.
20. Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Kalambaheti T, Nakayama EE, Shioda T, Khusmith S: Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Research and Therapy 2010; 7.
21. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004;319:1322-6.
22. Rotger M: CYP2B6: Explaining Efavirenz Pharmacokinetics. HIV Pharmacogenetics 2007; 2.
23. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-400.
24. Maimbo M, Kiyotani K, Mushiroda T, Masimirembwa C, Nakamura Y. CYP2B6 genotype is a strong predictor of systemic exposure 5 to efavirenz in HIV-infected Zimbabweans. Eur J Clin Pharmacol. 2012;68:267-71.
25. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS. 2009;23:2101-6.
26. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, Leon-Jimenez E. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41:681-90.
27. Matteelli A, Regazzi M, Villani P, De Iaco G, Cusato M, Carvalho AC. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res. 2007;5:349-53.
28. Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS. 2005;19:1541-3.
29. Friedland G, Khoo S, Jack C. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother. 2006;58:1299-302.
30. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother. 2001;45:382-92.
31. Nishimura Y, Kurata N, Sakurai E, Yasuhara H. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci. 2004;96:293-300.
32. Dhoro M, Ngara B, Kadzirange G, Nhachi C, Masimirembwa C. Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe. Curr HIV Res. 2013;11:481-90.
33. Gutierrez F, Navarro A, Padilla S. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41:1648-53.
34. Division of aids table for grading the severity of adult and pediatric adverse events. 2004.
35. Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, et al. High prevalence of the CYP2B6 516G>T (asterisk 6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2007;64:357-65.
36. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735-50.
37. Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, et al. High prevalence of the CYP2B6 516GT(asterisk 6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64:357-65.
38. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231-52.
39. Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, et al. Impact of CYP2B6 983 T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008;61:914-8.
40. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Decosterd L, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007;81:557-66.
41. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005;40:1358-61.
42. Nemaura T, Nhachi C, Masimirembwa C. Impact of gender, weight and CYP2B6 genotype on efavirenz exposure in patients on HIV/AIDS and TB treatment: Implications for individualising therapy. African J Pharm Pharmacol. 2012;6:2188-93.
43. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307:906-22.
44. Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS. 2010;5:61-9.
45. Manosuthi W, Sungkanuparph S, Tantanathip P. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Antimicrob Agents Chemother. 2009;53:4545-8.
46. Stöhr W, Back D, Dunn D. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther. 2008;13:675-85.
47. Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003;73:20-30.
48. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005;192:1931-42.
49. Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H. Team* aRMGAsS: Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097 s). HIV Clin Trials. 2009;10:343-55.
50. Cabrera SE, Santos D, Valverde MP, Dominguez-Gil A, Gonzalez F, Luna G. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother. 2009;53:2791-8.
51. Rekic D, Roshammar D, Mukonzo J, Ashton M. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol. 2011;71:536-43.
52. Thompson MA, Aberg JA, Hoy JF. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308:387-402.